{"filing":{"accession_number":"0000886163-26-000041","cik":"0000886163","ticker":"LGNYZ","company_name":"LIGAND PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"lgnd-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616326000041/lgnd-20260806.htm"},"events":[{"id":25354,"run_id":23004,"accession_number":"0000886163-26-000041","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Ligand Pharmaceuticals issued a press release on August 6, 2026, announcing financial results for the three and six months ended June 30, 2026. The disclosure includes detailed quarterly and year-to-date revenue, net income, and adjusted earnings per share figures, along with updated 2026 full-year guidance. This is a standard earnings release disclosing material financial results and forward guidance, furnished as Exhibit 99.1 under Item 2.02.","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26152,"accession_number":"0000886163-26-000041","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Ligand Pharmaceuticals issued a press release on August 6, 2026, announcing financial results for the three and six months ended June 30, 2026. The disclosure includes detailed quarterly and year-to-date revenue, net income, and adjusted earnings per share figures, along with updated 2026 full-year guidance. This is a standard earnings release disclosing material financial results and forward guidance, furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:34:24.601302+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26152,"accession_number":"0000886163-26-000041","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Ligand Pharmaceuticals issued a press release on August 6, 2026, announcing financial results for the three and six months ended June 30, 2026. The disclosure includes detailed quarterly and year-to-date revenue, net income, and adjusted earnings per share figures, along with updated 2026 full-year guidance. This is a standard earnings release disclosing material financial results and forward guidance, furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:34:24.601302+00:00","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-08-06"}]}